Core Laboratories (NYSE: CLB) reported Q2 EPS of $0.22, $0.02 worse than the analyst estimate of $0.24. Revenue for the quarter came in at $130.6 million versus the consensus estimate of $134.06 million.

GUIDANCE:

Core Laboratories sees Q3 2024 EPS of $0.23-$0.27, versus the consensus of $0.25. Core Laboratories sees Q3 2024 revenue of $131-137 million, versus the consensus of $135.9 million.

For earnings history and earnings-related data on Core Laboratories (CLB) click here.